TD Private Client Wealth LLC Acquires 141 Shares of Illumina, Inc. (NASDAQ:ILMN)

TD Private Client Wealth LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 58.5% in the third quarter, HoldingsChannel.com reports. The fund owned 382 shares of the life sciences company’s stock after buying an additional 141 shares during the quarter. TD Private Client Wealth LLC’s holdings in Illumina were worth $50,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina in the second quarter worth about $34,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the period. Private Trust Co. NA boosted its stake in shares of Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the period. Focused Wealth Management Inc bought a new position in shares of Illumina in the third quarter worth about $63,000. Finally, Hollencrest Capital Management bought a new position in shares of Illumina in the third quarter worth about $63,000. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ILMN. TD Cowen boosted their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Royal Bank of Canada boosted their target price on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. StockNews.com began coverage on Illumina in a research report on Thursday, August 29th. They issued a “buy” rating on the stock. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 target price on shares of Illumina in a research report on Tuesday, November 12th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.95.

Illumina Stock Up 0.4 %

Shares of NASDAQ:ILMN opened at $144.40 on Tuesday. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The stock has a market cap of $22.90 billion, a P/E ratio of -14.50 and a beta of 1.11. The business’s 50 day moving average is $144.35 and its 200 day moving average is $128.93. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.33 earnings per share. Sell-side analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.